DWA
BOLD

Dorsey Wright & Associates’s Audentes Therapeutics, Inc BOLD Stock Holding History

Dorsey Wright & Associates’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-500
Closed -$20K – 375
2018
Q3 		$20K Buy
+500
New +$18.6K ﹤0.01% 164

Other funds holding BOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Dorsey Wright & Associates's BOLD Position: Q4 2018 in Review

Dorsey Wright & Associates sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2018, closing a stake of 500 shares — an estimated $20K sold.

Dorsey Wright & Associates first reported a position in BOLD in Q3 2018 and held it in 1 quarter. The position peaked at $20K in Q3 2018. 126 funds tracked by Wall St. Rank hold BOLD as of Q4 2018.

  • Dorsey Wright & Associates reported no remaining Audentes Therapeutics, Inc position as of Q4 2018 after selling out during the quarter.
  • Dorsey Wright & Associates sold 500 Audentes Therapeutics, Inc shares in Q4 2018, an estimated $20K.
  • Dorsey Wright & Associates first reported a position in Audentes Therapeutics, Inc in Q3 2018 and held it in 1 quarter.
  • Dorsey Wright & Associates's Audentes Therapeutics, Inc position peaked at $20K in Q3 2018.
  • 126 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2018.

Based on Dorsey Wright & Associates's 13F filing for Q4 2018, filed 7 Jan 2019.